History of other malignancy within 5 years with the exception of prior SCCHN, adequately treated basal cell or squamous cell skin cancer, or carcinoma of the cervix
Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas
Prior malignancy; except for adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas
Diagnosis of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer
Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
History of prior malignancy that will interfere with the response evaluation (exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, any early stage (stage I) malignancy adequately resected for cure greater than 5 years previously).
Patient with previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions: basal cell or squamous cell carcinoma of the skin or prior malignancy that has been adequately treated and patient has been continuously disease free for >= 2 years
Patients with an active second malignancy other than adequately treated squamous or basal cell carcinoma of the skin
Prior invasive malignancy of other histology, with the exception of adequately treated basal or squamous cell carcinoma of the skin, or any other malignancy for which the patient does not currently require treatment, and/or has no evidence of disease for >= 2 years
History of another active cancer within 2 years prior to study drug dosing, excluding adequately treated basal cell or squamous cell carcinoma of the skin, cervical cancer in situ, or other adequately treated in situ carcinoma
Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years
History of another primary malignancy within 2 years prior to starting study treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ
Any concurrent or previous malignancy within 5 years prior to enrollment except for basal or squamous skin cancer, or carcinoma in situ of the cervix, or other non-invasive/in-situ neoplasm, all of which must have been adequately and radically treated. A subject with previous history of invasive malignancy (other than adequately and radically treated basal or squamous skin cancer) is eligible provided that she has been disease free for more than 5 years.
Any other malignancy within 3 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
adequately treated local basal cell or squamous cell carcinoma of the skin;
No prior malignancy is allowed except:\r\n* Adequately treated basal cell or squamous cell skin cancer or\r\n* In situ carcinoma of any site or\r\n* Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)
No prior malignancy is allowed except:\r\n* Adequately treated basal cell or squamous cell skin cancer or\r\n* In situ carcinoma of any site or\r\n* Other adequately treated malignancy for which the patient is currently disease free for at least one year
Second primary malignancy, other than in situ malignancies or adequately treated basal cell carcinoma of the skin or other malignancy treated at least 2 years previously with no evidence of recurrence
PHASE II: Previous or current invasive malignancies of other histologies requiring treatment within the last 2 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin
Myelodysplasia or any active malignancy other than HL, or < 5 years remission from any other prior malignancy, except adequately treated basal cell or squamous cell carcinoma
Patients with adequately treated basal cell or squamous cell carcinoma of the skin, adequately treated non-invasive carcinomas will be eligible
Adequately treated basal cell or squamous cell skin cancer
Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
Previous history of cancer, other than adequately treated basal cell or Stage 1 squamous cell carcinoma of the skin;
No prior malignancy is allowed except:\r\n* Adequately treated basal cell or squamous cell skin cancer or\r\n* In situ carcinoma of any site or\r\n* Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)
Previous or concurrent malignancy within the last 3 years with the exception of adequately treated skin basal or squamous cell with adequate wound healing
Diagnosis of another malignancy within 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
History of a malignancy, excluding adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ
DONOR: Malignancy within 10 years prior to donation of marrow, excluding adequately treated squamous cell skin cancer and basal cell carcinoma; treatment must have been completed (with the exception of hormonal therapy for breast cancer) with cure/remission status verified for at least 10 years at time of marrow harvest
Concurrent other malignancy with the exception of: \r\n* Cutaneous squamous cell and basal carcinomas\r\n* Adequately treated stage 1-2 malignancy\r\n* Adequately treated stage 3-4 malignancy that has been in remission for >= 2 years at the time of registration
Subjects must be at least 3 years from any prior malignancy and have no evidence of the malignancy at the time of enrollment; subjects with adequately treated squamous cell or basal cell carcinomas of the skin, multiple primary melanomas, or any carcinoma in situ will be allowed
Diagnosis of any other malignancy within 5 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.
Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry)
Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer
History of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin
Adequately treated basal cell or squamous cell skin cancer
Concurrent other malignancy with the exception of: a) cutaneous squamous cell and basal carcinomas, b) adequately treated stage 1-2 malignancy, c) adequately treated stage 3-4 malignancy that had been in remission for >= 2 years at the time of registration
Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years
Adequately treated basal or squamous cell skin cancer
Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri or breast
History of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin
Patients with prior malignancy will be excluded except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancers from which the patient has been disease-free for at least 5 years
History of other malignancy (i.e., excluding disease under study) within 3 years of randomization. Exceptions include: adequately-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or adequately treated non-metastatic prostate cancer.
history of any other malignancy treated within the last 5 years, other than squamous or basal cell skin cancer;
Patients with evidence of other cancer within 5 years, excluding adequately treated basal cell carcinoma or squamous cell carcinoma of the skin
Patients with presence of concurrent or active malignant disease (other than disease under study) within the last 12 months with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or non-melanomatous skin cancer.
adequately treated basal or squamous cell skin cancer or other localized non-melanoma skin cancer, or
Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix, squamous carcinoma of the skin, adequately controlled limited basal cell skin cancer, or synchronous primary endometrial cancer or prior primary endometrial cancer if protocol criteria are met
Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin;
No prior malignancy is allowed except:\r\n* Adequately treated basal cell or squamous cell skin cancer or\r\n* In situ carcinoma of any site or\r\n* Other adequately treated malignancy for which the patient is currently disease free for at least one year
adequately treated basal cell or squamous cell skin cancer
Prior history of or current malignancy other than adequately treated skin cancer (squamous cell cancer or basal cell carcinoma)
Any concurrent or previous malignancy within 5 years prior to enrollment except for adequately and radically treated basal or squamous skin cancer, or carcinoma in situ of the cervix, or other non-invasive/in-situ neoplasm. A subject with previous history of invasive malignancy (other than adequately and radically treated basal or squamous skin cancer or carcinomas in situ) is eligible provided that she has been disease free for more than 5 years.
